Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy

Domenico Italiano, Elisa Bianchini, Maura Ilardi, Roberto Cilia, Gianni Pezzoli, Renzo Zanettini, Laura Vacca, Fabrizio Stocchi, Placido Bramanti, Rosella Ciurleo, Giuseppe Di Lorenzo, Giovanni Polimeni, Cynthia de Luise, Douglas Ross, Peter Rijnbeek, Miriam Sturkenboom, Gianluca Trifirò

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

On June 2008, the European Medicines Agency (EMA) introduced changes to the Summary of Product Characteristics (SPC) for cabergoline and pergolide, to reduce the risk of cardiac valvulopathy in users of these drugs. To assess the effectiveness of EMA recommendations in Italian clinical practice, we retrospectively reviewed medical charts of patients with degenerative Parkinsonism treated with cabergoline in three large Italian clinics between January 2006 and June 2012. The prevalence and the severity of cardiac valve regurgitation were assessed in patients who stopped cabergoline therapy prior to June 2008 or continued therapy after that date. In addition, the proportion of patients undergoing echocardiographic examination in each cohort was evaluated. A total of 61 patients were available for evaluation. The proportion of patients who underwent a baseline echocardiographic examination increased from 64 % in the period before the 2008 SPC changes to 71 % among those who continued treatment after that date. However, only 18 and 29 % of patients underwent at least two echocardiographic examinations during the pre-SPC and cross-SPC change period, respectively. No severe cardiac valve regurgitation was documented in any of the study patients using cabergoline either prior or after 26th June 2008. Our findings show that the 2008 changes to the SPC resulted in an increase in physicians’ awareness of cabergoline-induced valvulopathy risk in Italy. However, only a small percentage of patients underwent serial echocardiography. Further efforts are needed to achieve better compliance with the prescribing guidelines for cabergoline treated patients in clinical practice.

Original languageEnglish
Pages (from-to)799-808
Number of pages10
JournalJournal of Neural Transmission
Volume122
Issue number6
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Heart Valves
Italy
Fibrosis
Pergolide
cabergoline
Parkinsonian Disorders
Drug Users
Echocardiography
Therapeutics
Guidelines
Physicians

Keywords

  • Cabergoline
  • Dopamine agonists
  • Italy
  • Valvulopathy

ASJC Scopus subject areas

  • Biological Psychiatry
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Medicine(all)

Cite this

Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. / Italiano, Domenico; Bianchini, Elisa; Ilardi, Maura; Cilia, Roberto; Pezzoli, Gianni; Zanettini, Renzo; Vacca, Laura; Stocchi, Fabrizio; Bramanti, Placido; Ciurleo, Rosella; Di Lorenzo, Giuseppe; Polimeni, Giovanni; de Luise, Cynthia; Ross, Douglas; Rijnbeek, Peter; Sturkenboom, Miriam; Trifirò, Gianluca.

In: Journal of Neural Transmission, Vol. 122, No. 6, 01.06.2015, p. 799-808.

Research output: Contribution to journalArticle

Italiano, D, Bianchini, E, Ilardi, M, Cilia, R, Pezzoli, G, Zanettini, R, Vacca, L, Stocchi, F, Bramanti, P, Ciurleo, R, Di Lorenzo, G, Polimeni, G, de Luise, C, Ross, D, Rijnbeek, P, Sturkenboom, M & Trifirò, G 2015, 'Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy', Journal of Neural Transmission, vol. 122, no. 6, pp. 799-808. https://doi.org/10.1007/s00702-014-1314-z
Italiano, Domenico ; Bianchini, Elisa ; Ilardi, Maura ; Cilia, Roberto ; Pezzoli, Gianni ; Zanettini, Renzo ; Vacca, Laura ; Stocchi, Fabrizio ; Bramanti, Placido ; Ciurleo, Rosella ; Di Lorenzo, Giuseppe ; Polimeni, Giovanni ; de Luise, Cynthia ; Ross, Douglas ; Rijnbeek, Peter ; Sturkenboom, Miriam ; Trifirò, Gianluca. / Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy. In: Journal of Neural Transmission. 2015 ; Vol. 122, No. 6. pp. 799-808.
@article{9b9ed838504045cabe9a1ea364d985d0,
title = "Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy",
abstract = "On June 2008, the European Medicines Agency (EMA) introduced changes to the Summary of Product Characteristics (SPC) for cabergoline and pergolide, to reduce the risk of cardiac valvulopathy in users of these drugs. To assess the effectiveness of EMA recommendations in Italian clinical practice, we retrospectively reviewed medical charts of patients with degenerative Parkinsonism treated with cabergoline in three large Italian clinics between January 2006 and June 2012. The prevalence and the severity of cardiac valve regurgitation were assessed in patients who stopped cabergoline therapy prior to June 2008 or continued therapy after that date. In addition, the proportion of patients undergoing echocardiographic examination in each cohort was evaluated. A total of 61 patients were available for evaluation. The proportion of patients who underwent a baseline echocardiographic examination increased from 64 {\%} in the period before the 2008 SPC changes to 71 {\%} among those who continued treatment after that date. However, only 18 and 29 {\%} of patients underwent at least two echocardiographic examinations during the pre-SPC and cross-SPC change period, respectively. No severe cardiac valve regurgitation was documented in any of the study patients using cabergoline either prior or after 26th June 2008. Our findings show that the 2008 changes to the SPC resulted in an increase in physicians’ awareness of cabergoline-induced valvulopathy risk in Italy. However, only a small percentage of patients underwent serial echocardiography. Further efforts are needed to achieve better compliance with the prescribing guidelines for cabergoline treated patients in clinical practice.",
keywords = "Cabergoline, Dopamine agonists, Italy, Valvulopathy",
author = "Domenico Italiano and Elisa Bianchini and Maura Ilardi and Roberto Cilia and Gianni Pezzoli and Renzo Zanettini and Laura Vacca and Fabrizio Stocchi and Placido Bramanti and Rosella Ciurleo and {Di Lorenzo}, Giuseppe and Giovanni Polimeni and {de Luise}, Cynthia and Douglas Ross and Peter Rijnbeek and Miriam Sturkenboom and Gianluca Trifir{\`o}",
year = "2015",
month = "6",
day = "1",
doi = "10.1007/s00702-014-1314-z",
language = "English",
volume = "122",
pages = "799--808",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer-Verlag Wien",
number = "6",

}

TY - JOUR

T1 - Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy

AU - Italiano, Domenico

AU - Bianchini, Elisa

AU - Ilardi, Maura

AU - Cilia, Roberto

AU - Pezzoli, Gianni

AU - Zanettini, Renzo

AU - Vacca, Laura

AU - Stocchi, Fabrizio

AU - Bramanti, Placido

AU - Ciurleo, Rosella

AU - Di Lorenzo, Giuseppe

AU - Polimeni, Giovanni

AU - de Luise, Cynthia

AU - Ross, Douglas

AU - Rijnbeek, Peter

AU - Sturkenboom, Miriam

AU - Trifirò, Gianluca

PY - 2015/6/1

Y1 - 2015/6/1

N2 - On June 2008, the European Medicines Agency (EMA) introduced changes to the Summary of Product Characteristics (SPC) for cabergoline and pergolide, to reduce the risk of cardiac valvulopathy in users of these drugs. To assess the effectiveness of EMA recommendations in Italian clinical practice, we retrospectively reviewed medical charts of patients with degenerative Parkinsonism treated with cabergoline in three large Italian clinics between January 2006 and June 2012. The prevalence and the severity of cardiac valve regurgitation were assessed in patients who stopped cabergoline therapy prior to June 2008 or continued therapy after that date. In addition, the proportion of patients undergoing echocardiographic examination in each cohort was evaluated. A total of 61 patients were available for evaluation. The proportion of patients who underwent a baseline echocardiographic examination increased from 64 % in the period before the 2008 SPC changes to 71 % among those who continued treatment after that date. However, only 18 and 29 % of patients underwent at least two echocardiographic examinations during the pre-SPC and cross-SPC change period, respectively. No severe cardiac valve regurgitation was documented in any of the study patients using cabergoline either prior or after 26th June 2008. Our findings show that the 2008 changes to the SPC resulted in an increase in physicians’ awareness of cabergoline-induced valvulopathy risk in Italy. However, only a small percentage of patients underwent serial echocardiography. Further efforts are needed to achieve better compliance with the prescribing guidelines for cabergoline treated patients in clinical practice.

AB - On June 2008, the European Medicines Agency (EMA) introduced changes to the Summary of Product Characteristics (SPC) for cabergoline and pergolide, to reduce the risk of cardiac valvulopathy in users of these drugs. To assess the effectiveness of EMA recommendations in Italian clinical practice, we retrospectively reviewed medical charts of patients with degenerative Parkinsonism treated with cabergoline in three large Italian clinics between January 2006 and June 2012. The prevalence and the severity of cardiac valve regurgitation were assessed in patients who stopped cabergoline therapy prior to June 2008 or continued therapy after that date. In addition, the proportion of patients undergoing echocardiographic examination in each cohort was evaluated. A total of 61 patients were available for evaluation. The proportion of patients who underwent a baseline echocardiographic examination increased from 64 % in the period before the 2008 SPC changes to 71 % among those who continued treatment after that date. However, only 18 and 29 % of patients underwent at least two echocardiographic examinations during the pre-SPC and cross-SPC change period, respectively. No severe cardiac valve regurgitation was documented in any of the study patients using cabergoline either prior or after 26th June 2008. Our findings show that the 2008 changes to the SPC resulted in an increase in physicians’ awareness of cabergoline-induced valvulopathy risk in Italy. However, only a small percentage of patients underwent serial echocardiography. Further efforts are needed to achieve better compliance with the prescribing guidelines for cabergoline treated patients in clinical practice.

KW - Cabergoline

KW - Dopamine agonists

KW - Italy

KW - Valvulopathy

UR - http://www.scopus.com/inward/record.url?scp=84930226854&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930226854&partnerID=8YFLogxK

U2 - 10.1007/s00702-014-1314-z

DO - 10.1007/s00702-014-1314-z

M3 - Article

VL - 122

SP - 799

EP - 808

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 6

ER -